Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

Adams, who served as surgeon general during the first Trump administration, said Kennedy's assertions about the efficacy of ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms ...

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...